Skip to main content
Premium Trial:

Request an Annual Quote

Roche Grants Merck Access to p53 Chip

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Roche Molecular Systems today said that it has formed a research collaboration with Merck subsidiary Merck Sharp & Dohme, under which the drug firm will have access to Roche's microarray-based AmpliChip p53 Test for research purposes.

The chip, which utilizes Affymetrix's microarray technology, is designed to detect mutations in the tumor suppressor gene p53. The test could potentially lead to better treatment outcomes for cancer patients by determining which patients would most likely respond to investigational drug candidates.

Terms of the alliance were not disclosed.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.